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Abstract: Bevacizumab (10 mg/kg every 2 weeks), in combination with interferon alpha-2a 
(IFN), is an effective option for ﬁ  rst-line therapy for advanced and/or metastatic renal cell 
carcinoma (RCC). Two phase III trials clearly show signiﬁ  cant improvements in progression-free 
survival and response rate in patients with treatment-naïve metastatic RCC receiving bevaci-
zumab combined with IFN compared with IFN. The dose of IFN, which was initiated at 9 MIU 
3 times a week in these trials, can be reduced to effectively manage IFN-related side effects 
without compromising the efﬁ  cacy of bevacizumab plus IFN. Bevacizumab has good tolerability 
with manageable side effects, both alone and in combination with other agents; the tolerability 
proﬁ  le of bevacizumab in combination with IFN is consistent with the well-characterized and 
well-established proﬁ  les of these therapies. The tolerability of bevacizumab combined with 
IFN and the ﬂ  exibility to manage IFN-related side effects are important considerations when 
selecting ﬁ  rst-line therapy. With a number of options now available for RCC therapy, optimizing 
their use is a key consideration in improving patient beneﬁ  t.
Keywords: bevacizumab (Avastin®), interferon alpha, efﬁ  cacy, tolerability, renal cell carcinoma 
(RCC), low-dose interferon
Bevacizumab development
Vascular endothelial growth factor (VEGF) is a ligand that primarily acts upon vascular 
endothelial cells and is produced by a number of different cell types (Leung et al 
1989; Ferrara et al 2003; Ferrara 2004). Binding of VEGF to its main receptor, VEGF 
receptor-2, results in an array of biological effects including increased vascular perme-
ability, induction of proliferation and migration of endothelial cells (angiogenesis), 
and promotion of the survival of immature endothelial cells via apoptosis inhibition. 
As such it is a key pro-angiogenic molecule, playing a critical role in the angiogen-
esis essential to physiological processes such as embryogenesis and skeletal growth 
(Carmeliet et al 1996; Ferrara et al 1998; Gerber et al 1999; Bloch et al 2000). However, 
in adulthood, the physiological role of VEGF is limited and includes processes such 
as wound healing and the female reproductive function.
VEGF is a key mediator of angiogenesis in cancer (Carmeliet 2005). When oxygen 
and nutrient levels are insufﬁ  cient to continue proliferation, tumors become hypoxic 
and further growth is prevented. To facilitate further tumor growth, angiogenesis is 
essential and the production of growth factors such as VEGF by the tumor in response 
to cellular hypoxia is a key mediator. VEGF is continuously expressed throughout 
the development of many tumor types, and is the only angiogenic factor known to be 
present throughout the entire tumor life cycle (Folkman 2005). Despite the resulting 
tumor-associated vasculature being abnormal and inefﬁ  cient, it is vital for tumor 
survival and proliferation.
Targeting tumor vasculature as a means of therapeutic intervention was ﬁ  rst 
proposed by Folkman in 1971 (Folkman 1971; Folkman et al 1971). The identiﬁ  cation Biologics: Targets & Therapy 2008:2(3) 518
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and characterization of VEGF in the 1980s (Senger et al 
1983; Senger et al 1986; Ferrara and Henzel 1989) made 
this mode of therapy a real prospect, and targeting VEGF as 
a means of preventing angiogenesis led to the development 
of bevacizumab (Avastin®). Bevacizumab is a recombinant 
humanized monoclonal immunoglobulin G1 (IgG1) mono-
clonal antibody (mAb) that directly inhibits VEGF. It was 
developed from the murine anti-VEGF mAb after A4.6.1, 
which was shown to be effective in suppressing the growth 
of tumour xenografts in animal models (Kim et al 1993; 
Warren et al 1995). However, as a foreign protein, A4.6.1 
would be unsuitable for use in humans because of the immune 
response it would invoke. In addition to potentially causing 
allergic reactions, its bioavailability and half-life would be 
greatly limited. Therefore, the murine anti-VEGF mAb was 
humanized by site-directed mutagenesis to produce bevaci-
zumab, which is 93% human and 7% murine and recognizes 
all major isoforms of human VEGF with a similar binding 
afﬁ  nity to the murine antibody (Kd = 8 × 10–10 M) (Presta 
et al 1997). Bevacizumab binding to VEGF sterically hinders 
VEGF ligation to its receptors on vascular endothelial cells 
(Kim et al 1992).
A number of effects on tumor vasculature are observed 
with sustained inhibition of VEGF using bevacizumab. 
Regression of existing tumor microvasculature, normaliza-
tion of surviving tumor vasculature and inhibition of the 
formation of new vasculature are all seen with bevacizumab 
therapy (Presta et al 1997; Willett et al 2004). It has also been 
suggested that bevacizumab may reverse tumor-associated 
immune suppression as well as improving concomitant drug 
delivery into the tumor (Jain 2002; Wildiers et al 2003; Tong 
et al 2004). The requirement for continued VEGF inhibi-
tion for continued tumor growth inhibition is highlighted 
by studies showing that withdrawal of anti-VEGF therapy 
results in rapid regrowth of tumor vasculature, suggesting 
that anti-VEGF therapy should be continued until disease 
progression (Mancuso et al 2006).
Initial clinical trials of bevacizumab showed that it was 
well tolerated when administered alone and in combina-
tion with various chemotherapy regimens to patients with 
solid tumors (Gordon et al 2001; Margolin et al 2001). 
Subsequent phase II trials established promising efﬁ  cacy 
and tolerability when used in combination with standard 
chemotherapy regimens for colorectal cancer (CRC) and 
non-small cell lung cancer (NSCLC) (Kabbinavar et al 2003; 
Johnson et al 2004). Based on data from a phase III trial 
of irinotecan/5-ﬂ  uorouracil/leucovorin (IFL) plus placebo 
vs IFL plus bevacizumab in patients with metastatic CRC, 
which demonstrated a signiﬁ  cant overall survival (OS) 
beneﬁ  t for the combination, the US Food and Drug Admin-
istration (FDA) approved bevacizumab as part of ﬁ  rst-line 
treatment for metastatic CRC in February 2004, making 
bevacizumab the ﬁ  rst anti-VEGF therapy to be approved 
for clinical use (Ferrara et al 2005). Bevacizumab has now 
also been approved as part of ﬁ  rst-line therapy for metastatic 
breast cancer and advanced NSCLC in many countries 
worldwide. As a result of extensive clinical experience 
from more than 10 completed phase III trials and more 
than 250,000 patients treated worldwide, bevacizumab’s 
tolerability profile is well characterized. In December 
2007, the European Medicines Agency (EMEA) approved 
bevacizumab, in combination with interferon alpha-2a 
(IFN), as ﬁ  rst-line treatment for patients with advanced 
and/or metastatic renal cell carcinoma (RCC) (Roche Media 
News 2007).
RCC: disease overview
RCC represents 3% of all cancers (Ferlay et al 2007; Jemal 
et al 2008) and approximately 85% of all renal tumors 
(Motzer et al 1996), more than 200,000 cases of RCC are 
diagnosed annually worldwide. RCC affects more men than 
women (approximately in a ratio of 2:1) and its incidence 
peaks in people aged 60–80 years (Corgna et al 2007). 
Improved imaging techniques and more incidental ﬁ  ndings 
may partly be responsible for an observed increase in the 
overall incidence of RCC in recent years (Lipworth et al 
2006; Corgna et al 2007). Over 100,000 deaths are attrib-
uted to RCC each year (Ferlay et al 2007; Jemal et al 2008) 
although mortality rates appear to be stabilizing, and in some 
cases declining, following steady increases in mortality rate 
over the past few decades (Bosetti et al 2008; Karim-Kos et al 
2008; Levi et al 2008). The reasons for this improvement are 
currently undetermined.
The proximal renal tubular epithelium is the primary 
site of origin for RCC, which can be categorized into 
4 main subtypes (Cheville et al 2003): clear cell, papillary, 
chromophobic and collecting duct. Clear cell RCC accounts 
for approximately 85% of all RCC tumors (Figure 1) 
(Cheville et al 2003).
Major risk factors linked with the development of 
RCC include smoking, obesity, hypertension and chronic 
dialysis (Lipworth et al 2006), but RCC occurs in both 
sporadic and hereditary forms, with at least 4 hereditary 
syndromes recognized (Linehan et al 2003; Vira et al 
2007): von Hippel-Lindau (VHL) syndrome (characterized 
by mutations/deletions of the VHL tumor suppressor gene); Biologics: Targets & Therapy 2008:2(3) 519
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hereditary papillary renal carcinoma (characterized by 
c-MET proto-oncogene mutations); hereditary leiomyo-
matosis RCC (characterized by fumarate hydratase gene 
mutations); Birt-Hogg-Dubé (BHD) syndrome, (character-
ized by BHD tumor suppressor gene mutation/deletion). 
Mutations in the VHL gene are also found in sporadic cases 
of RCC, occurring in 70% of cases sporadic clear cell 
RCC (Linehan et al 2003; Vira et al 2007). Considering 
that clear cell RCC represents 80%–85% of all cases 
of RCC (Cheville et al 2003), VHL gene mutations are 
the most frequent genetic aberrations associated with 
RCC development.
The high degree of vascularization and high expression 
of VEGF by RCC tumors highlights the fact that RCC is a 
VEGF-driven disease whose development is directly linked 
to VEGF overexpression and angiogenesis (Herbst et al 
1998; Jacobsen et al 2004; Kaelin 2007). Overexpression of 
VEGF in RCC results from the excess activity of hypoxia-
inducible transcription factors such as via hypoxia-inducible 
factor-α (HIFα) (Kaelin 2005). Under normal oxygen 
concentrations, the VHL protein controls HIFα expression 
by targeting it for proteosomal degradation (George and 
Kaelin 2003; Iliopoulos 2006). However, the formation of 
VHL protein complexes is suppressed when cells become 
hypoxic, allowing HIFα expression and the production of 
pro-angiogenic growth factors such as VEGF. In RCC, 
mutation or inactivation of the VHL protein is common 
(Linehan et al 2003; Vira et al 2007) and results in an 
inability to degrade HIFα in the presence of normal oxygen 
levels (Kaelin 2007), ultimately leading to increased VEGF 
expression, angiogenesis and tumor growth. The central role 
VEGF plays in the pathophysiology of RCC makes RCC 
a logical indication for therapy with the direct anti-VEGF 
inhibitor bevacizumab.
Historical management options 
in RCC
Nephrectomy is the primary treatment for patients with 
RCC presenting with stages I–III disease (tumors limited to 
the kidney or tumors that extend beyond the kidney, including 
regional lymph nodes, but without distant metastasis) 
(Ljungberg et al 2007; National Comprehensive Cancer 
Network 2008) and can represent a curative option (National 
Comprehensive Cancer Network 2008). However, approxi-
mately 30% of patients present with advanced and/or metastatic 
disease (ie, stage IV tumors, which are those that have metas-
tasized or invaded adjacent organs) (Corgna et al 2007) where 
surgery is usually only palliative. Treatment options for patients 
who have metastatic disease or are at high risk of recurrence 
following nephrectomy are limited. RCC is generally refractory 
to conventional cancer therapies, and as such chemotherapy, 
radiotherapy and hormone therapy have no established roles 
in the management of RCC (Corgna et al 2007).
Observations of spontaneous regression of solitary 
metastases, regression of metastases after nephrectomy, and 
the presence of lymphocytes inﬁ  ltrating the primary tumor 
following IFN and interleukin-2 (IL-2) therapy suggested 
that these responses may be immune-mediated. IFN and IL-2 
are 2 cytokines shown to provide beneﬁ  t to some patients 
with RCC (Coppin et al 2005; Yang and Childs 2006). As the 
only therapeutic options available for patients with advanced 
and/or metastatic disease, immunotherapy was the standard 
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Figure 1 Clear cell RCC represents the majority of all RCC tumors.
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of care for patients with metastatic RCC for approximately 
25 years from the 1980s (Porta et al 2007).
Approved in Europe and Japan for metastatic RCC 
therapy, IFN has immunomodulatory, anti-viral, anti-
proliferative and anti-angiogenic properties. IL-2 is the 
only FDA-approved cytokine therapy for metastatic RCC. 
The overall objective response rate (ORR) with IFN therapy 
is approximately 15% (range 0%–29%) (Fossa 2000) 
and 17%–27% with high-dose IL-2 therapy (Parton et al 
2006; McDermott and Rini 2007). An OS beneﬁ  t has been 
demonstrated for IFN (Medical Research Council Renal 
Cancer Collaborators 1999; Pyrhonen et al 1999). However, 
the beneﬁ  t of both of these agents is limited to selected 
patients, with the Memorial-Sloan Kettering Cancer Center 
(MSKCC) risk criteria most commonly being used to select 
patients with good prognosis for therapy (Motzer et al 2002; 
Motzer et al 2004); a recent trial showed no beneﬁ  t from 
IFN therapy in patients with intermediate risk (Negrier et al 
2007). Common tolerability issues associated with IFN 
therapy include fatigue, fever, chills, myalgia and depression 
(Jonasch and Haluska 2001) and the signiﬁ  cant toxicity of 
high-dose IL-2 regimens limits their use.
How is bevacizumab evolving 
the way in which we treat patients 
with metastatic RCC?
Phase II trials of bevacizumab in RCC
Efﬁ  cacy
Two key phase II trials of bevacizumab in RCC have 
been conducted: AVF0890s (Yang et al 2003) and RACE 
(Bukowski et al 2007). AVF0890s recruited 116 patients 
with metastatic RCC who were not optimal candidates 
for IL-2 therapy or had previously not responded to this 
therapy. This trial was a randomized, placebo-controlled, 
double-blind trial of bevacizumab monotherapy. Patients 
were randomized to 1 of 3 treatment arms: placebo (n = 40), 
bevacizumab 3 mg/kg (n = 37) or 10 mg/kg (n = 39). The 
results from this trial showed that median time to progres-
sion (TTP) was signiﬁ  cantly longer for the bevacizumab 
10 mg/kg arm than the placebo arm (4.8 vs 2.5 months; 
hazard ratio [HR] = 2.55; p   0.001) with 10% of patients 
achieving a partial response (PR). The median TTP for the 
bevacizumab 3 mg/kg arm was not signiﬁ  cantly greater than 
the placebo arm (TTP 3.0 months; HR = 1.26; p = 0.053) and 
no patients achieved a PR. Possibly due to the cross-over of 
the placebo-treated patients to receive bevacizumab after dis-
ease progression, OS was not signiﬁ  cantly different between 
the 3 treatment arms (p   0.20 for all comparisons). The 
positive results observed with bevacizumab 10 mg/kg pro-
vided the rationale for further studying this dose in RCC.
A substantial number of patients receiving bevacizumab 
in this trial, while not having sufﬁ  cient tumor shrinkage 
to be classiﬁ  ed as having a PR or complete response, had 
mixed tumor responses (Yang 2004). Overall, when patients 
stopped receiving bevacizumab 10 mg/kg, tumor burden at 
progression was less than at baseline. The strict criteria for 
progression (a 25% increase in the perpendicular diameters of 
any lesion constituted progression) may have led to premature 
withdrawal of therapy, even though progression occurred 
only in a minority of their lesions. These observations high-
light the potential beneﬁ  t of continuing bevacizumab despite 
limited progression.
The second phase II trial, RACE, evaluated bevacizumab 
alone or in combination with erlotinib (Tarceva®) in patients 
with metastatic RCC. Erlotinib is a small-molecule tyrosine 
kinase inhibitor (TKI) of epidermal growth factor receptor 
(EGFR). EGFR and VEGF are both over expressed in many 
tumors, and VEGF has been implicated in resistance to 
EGFR-inhibiting agents (Viloria-Petit et al 2001). RACE 
was a randomized, double-blind, placebo-controlled trial of 
104 patients with metastatic RCC who had received no prior 
systemic therapy. The treatment arms consisted of bevaci-
zumab 10 mg/kg every 2 weeks and either erlotinib 150 mg 
or placebo daily. Treatment continued for a maximum of 
24 months or until toxicity or disease progression. A median 
progression-free survival (PFS) of 8.5 months was achieved 
with bevacizumab monotherapy; this was not signiﬁ  cantly 
improved by the addition of erlotinib (9.9 months; HR: 0.86; 
95% conﬁ  dence interval [CI]: 0.50–1.49). The ORR was also 
similar (13% with bevacizumab plus placebo vs 14% with 
bevacizumab plus erlotinib). One complete response was, 
however, noted in the bevacizumab plus erlotinib arm. The 
median survival duration with bevacizumab plus erlotinib 
was 20 months but median OS with bevacizumab plus pla-
cebo had not been reached, possibly due to the greater use of 
second-line therapies in the bevacizumab only arm compared 
with the bevacizumab plus erlotinib arm (32% vs 14%).
Tolerability
Bevacizumab 10 mg/kg every 2 weeks as a single agent 
is generally well tolerated in RCC. In the phase II trials 
discussed above, bevacizumab therapy was associated with 
manageable side effects, most commonly hypertension, 
proteinuria and epistaxis. These events are recognized 
side effects of bevacizumab based on data from trials in Biologics: Targets & Therapy 2008:2(3) 521
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various tumor types (Hurwitz et al 2004; Sandler et al 2006; 
Miller et al 2007). Hypertension was the most common 
side effect in both studies. In AVF0890s, 36% of patients 
(20% grade 3) developed hypertension on the bevacizumab 
10 mg/kg arm compared with only 5% on the placebo arm 
(no grade 3 events). In the RACE trial, grade 3 hypertension 
developed in 26% of patients receiving bevacizumab plus 
placebo and 31% bevacizumab plus erlotinib. No grade 
4 hypertension was reported. Hypertension was managed 
with oral antihypertensive medication.
The second most frequent side effect was asymptomatic 
proteinuria. Grade 3 proteinuria developed in 8% of patients 
receiving bevacizumab 10 mg/kg (AVF0890s trial) and 
5.7% of those receiving bevacizumab plus placebo (RACE 
trial). In the bevacizumab plus erlotinib arm of the RACE 
trial, 2 patients developed grade 4 proteinuria. The RACE trial 
also reported grade 3/4 hemorrhage in 3.8% of patients in the 
bevacizumab plus placebo arm and 5.9% of patients in the 
bevacizumab plus erlotinib arm. As expected, only patients 
in the bevacizumab plus erlotinib arm reported grade 3 rash 
(16%) and diarrhea (7.8%).
Long-term treatment with bevacizumab also appears 
feasible and well tolerated. Four patients from the AVF0890s 
trial received bevacizumab treatment for 3–5 years, 
with proteinuria the only signiﬁ  cant event attributable to 
bevacizumab (Yang 2004).
These data indicate that bevacizumab causes side effects 
typical of inhibition of the VEGF pathway in patients with 
RCC; similar events are observed at a similar incidence in 
patients treated with TKIs such as sunitinib, which inhibit 
VEGF receptors as well as other TKIs, although such 
agents also cause non-VEGF-speciﬁ  c events such as hand-
foot syndrome and myelosuppression (Motzer et al 2007). 
The tolerability of single-agent bevacizumab also created 
a rationale for trials examining its efﬁ  cacy and safety in 
combination with the existing standard of care, which was 
IFN at the time that phase III trials were initiated.
AVOREN: pivotal phase III trial 
of bevacizumab, in combination 
with interferon alpha, in RCC
Trial design
The efﬁ  cacy and safety of bevacizumab, in combination 
with IFN, as first-line therapy was investigated in the 
ongoing phase III AVOREN (Avastin and Roferon in renal 
cell carcinoma [BO17705]) trial (Escudier et al 2007b). 
Bevacizumab was combined with IFN because this was the 
standard therapy and as earlier clinical trials had suggested 
that bevacizumab could be combined with other therapies 
without signiﬁ  cantly affecting their tolerability (Hurwitz et al 
2004; Sandler et al 2006; Miller et al 2007). In addition, it 
was believed that using bevacizumab in combination with 
IFN could maximize patient outcomes because the proposed 
mechanisms of action of bevacizumab and IFN suggested 
that these agents may have complementary and synergistic 
effects (Ferrara et al 2005; Ferrantini et al 2007).
To be considered for inclusion into this trial patients 
must have had conﬁ  rmed metastatic RCC of predominantly 
clear cell histology (  50% clear cell if mixed) and prior 
nephrectomy for primary RCC. Patients must also have 
had measurable or non-measurable disease according to 
RECIST, a Karnofsky performance status (KPS)  70% and 
no proteinuria at baseline ( 0.5 g of protein in a 24-hour 
urine collection). Patients were excluded if they had had 
prior systemic treatment for metastatic RCC, undergone 
major surgery within 28 days, had evidence of central 
nervous system (CNS) metastases or spinal cord compres-
sion, uncontrolled hypertension or cardiovascular disease. 
Patients with evidence of  bleeding diathesis or coagulopathy 
and those receiving full therapeutic doses of oral or parenteral 
anticoagulants were also ineligible.
Between June 2004 and October 2005, 649 patients with 
metastatic disease were enrolled. On a 1:1 basis, patients were 
randomized to receive IFN 9 MIU 3 times a week plus placebo 
or bevacizumab 10 mg/kg every 2 weeks plus IFN. IFN therapy 
was stopped after 52 weeks, but patients could continue to 
receive single-agent bevacizumab/placebo beyond this time 
until disease progression. The primary objective of this trial is 
OS and secondary endpoints included PFS, TTP, and ORR.
Overall efﬁ  cacy
An 89% improvement in median PFS was observed with 
bevacizumab plus IFN therapy compared with IFN plus 
placebo (Escudier et al 2007b). The addition of  bevacizumab 
to IFN signiﬁ  cantly increased PFS from 5.4 to 10.2 months 
(HR = 0.63, p = 0.0001). ORR was also improved with 
bevacizumab plus IFN compared with IFN plus placebo 
(31% vs 13%). The median OS had not been reached in the 
bevacizumab plus IFN group at the time of reporting. Final 
OS data are expected at the end of 2008. The median OS in 
the IFN plus placebo arm is 19.8 months.
Efﬁ  cacy in patient subgroups
The addition of bevacizumab to IFN improves PFS in all sub-
groups analyzed (Bracarda et al 2007a; Melichar et al 2008). Biologics: Targets & Therapy 2008:2(3) 522
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Patients in both favorable (n = 180) and intermediate 
(n = 363) MSKCC risk groups showed improvements in 
PFS (median PFS 12.9 vs 7.6 months, HR = 0.60; median 
PFS 10.2 vs 4.5 months, HR = 0.55, respectively). Despite 
patients in the poor MSKCC risk category (n = 54) having 
improved PFS (HR = 0.81; p = 0.457), this did not reach 
statistical signiﬁ  cance.
Patients with both clear cell RCC histology (n = 564; 
median PFS 10.2 vs 5.5 months, HR = 0.64; 95% CI: 0.53–0.77) 
and mixed RCC histology (n = 85; median PFS 5.7 vs 
2.9 months, HR = 0.60; 95% CI: 0.33–0.85) had PFS beneﬁ  t. 
Signiﬁ  cant improvement in PFS was also seen in patients 
aged  65 years (n = 239; HR = 0.77; 95% CI: 0.58–1.03) 
and  65 years (n = 410; HR = 0.54; 95% CI: 0.43–0.68). 
Furthermore, the PFS beneﬁ  t of bevacizumab plus IFN 
was observed in patients with reduced kidney function 
(as assessed by creatinine clearance [CLcr]) (high/normal 
CLcr: n = 131; HR = 0.60 [95% CI: 0.46–0.79]; low CLcr: 
n = 191; HR = 0.65 [95% CI: 0.51–0.82]) and VEGF 
levels below (HR = 0.44; 95% CI: 0.32–0.64) and above 
(HR = 0.66; 95% CI: 0.49–0.93) the baseline median. 
Finally, PFS beneﬁ  t was observed in patients with either 
single or multiple metastatic sites treated with bevacizumab 
to IFN and regardless of whether the sum of baseline tumor 
measurements was above or below the median. Increased 
response rates were also observed in all patient subgroups 
treated with bevacizumab plus IFN.
Overall tolerability
Both bevacizumab and IFN have predictable and well-
established tolerability proﬁ  les (Jonasch and Haluska 2001; 
Yang et al 2003; Coppin et al 2005; Bukowski et al 2007) 
and the tolerability proﬁ  le for bevacizumab plus IFN in the 
AVOREN trial is consistent with the side effects previously 
reported for these agents. Dose intensities (percentage of 
planned total dose) of bevacizumab/placebo and IFN were 
similar in the 2 treatment arms (92% bevacizumab plus 
IFN vs 96% IFN plus placebo for the bevacizumab/placebo 
arms and 91% bevacizumab plus IFN vs 96% IFN plus pla-
cebo for the IFN arms). The incidence of grade 3/4 events 
associated with IFN therapy increased from 15% to 23% with 
the addition of bevacizumab to IFN. However, the duration 
of IFN therapy was longer in the bevacizumab plus IFN arm 
compared with the control arm (7.8 vs 4.6 months). The 
median duration of bevacizumab treatment in the bevaci-
zumab plus IFN arm was 9.7 months in contrast to 5.1 months 
in the placebo arm. The incidence of bevacizumab-associated 
grade 3/4 events included hypertension (7%), proteinuria 
(4%), bleeding (3%), arterial and venous thromboembolic 
events (3%), gastrointestinal perforation (1%), and wound 
healing complications ( 1%).
Tolerability in patient subgroups
Analysis of patient subgroups showed that the dose intensity 
of bevacizumab was similar in subgroups deﬁ  ned by CLcr 
and by age. The dose intensity of IFN was lower in patients 
with low CLcr (IFN plus placebo 92%; bevacizumab plus 
IFN 78%) and  65 years (IFN plus placebo 92%; bevaci-
zumab plus IFN 82%) than in those with normal/high CLcr 
(IFN plus placebo 99%; bevacizumab plus IFN 87%) 
and  65 years (IFN plus placebo 99%; bevacizumab plus 
IFN 92%).
In patients in the favorable and intermediate MSKCC risk 
groups, the incidence of grade  3 adverse events (AEs; mean 
number of AEs per patients) in the bevacizumab plus IFN 
arm was slightly higher than in the placebo arm: 1.3 and 1.2, 
respectively, compared with 1.0 and 0.8 in the placebo arm. 
No difference in the incidence of grade  3 AEs was found in 
patients in the poor MSKCC risk group. A higher incidence of 
grade  3 AEs (bevacizumab 66%; IFN 48%) was observed 
in both treatment arms in patients aged  65 years compared 
with patients  65 years (bevacizumab 58%; IFN 45%). 
Patients aged  65 years in the bevacizumab arm had a higher 
incidence of fatigue and asthenia. The overall incidences of 
grade  3 AEs were similar in patients receiving bevacizumab 
irrespective of kidney performance, with no difference in the 
incidence of bevacizumab-associated AEs.
Overall, the tolerability of bevacizumab plus IFN was 
as expected based on data from previous trials of these agents 
as monotherapy. The tolerability in various subgroups indi-
cates that neither age nor renal function should be used to 
make decisions on whether to treat patients with bevacizumab 
plus IFN.
CALGB 90206: a second phase III trial 
of bevacizumab plus IFN in metastatic 
RCC
Trial design
Cancer and Leukemia Group B (CALGB) trial 90206 is an 
ongoing phase III trial evaluating the efﬁ  cacy and safety of 
adding bevacizumab to IFN in the treatment of metastatic 
RCC (Rini et al 2008). It is a randomized, open-label study, 
being conducted in the US by CALGB, a US cooperative 
group sponsored by the National Cancer Institute. It should 
be noted that this trial differs from AVOREN in that no 
placebo was used and the trial is not blinded.Biologics: Targets & Therapy 2008:2(3) 523
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Eligibility criteria for this study included no prior 
systemic treatment for RCC, conﬁ  rmed metastatic RCC 
with a clear cell component, KPS   70%, measurable or 
evaluable disease (by RECIST), adequate end-organ function, 
no CNS metastases, no uncontrolled hypertension, and no 
venous thrombosis within 12 months or arterial thrombosis 
within 6 months. Prior nephrectomy was not a requirement 
for recruitment to this study.
A total of 732 patients were enrolled on to this trial 
and randomized to receive bevacizumab (10 mg/kg every 
2 weeks) plus IFN (9 MIU 3 times a week) or IFN alone. The 
primary endpoint for this study is OS. Secondary endpoints 
include PFS, ORR, and safety.
Efﬁ  cacy and tolerability
Based on the recommendation of the Data and Safety Moni-
toring Board (DSMB), a pre-planned interim analysis of the 
trial results was released. These data conﬁ  rmed the results 
of AVOREN, showing that PFS was signiﬁ  cantly extended 
by the addition of bevacizumab to IFN (8.5 months [95% 
CI: 7.5–9.7] vs 5.2 months [95% CI: 3.1–5.6]; HR = 0.71 
[95% CI: 0.61–0.83]). The addition of bevacizumab to IFN 
also improved ORR compared with IFN alone (25.5% vs 
13.1%). The DSMB will continue to monitor OS until the 
data are mature.
Analyses of patients categorized by their MSKCC risk 
status showed the addition of bevacizumab to IFN improved 
PFS in all groups. Signiﬁ  cant improvements in PFS were 
observed in both the favorable (n = 192) and intermedi-
ate (n = 465) MSKCC risk groups (median PFS 11.1 vs 
5.7 months, p = 0.0012; median PFS 8.4 vs 5.3 months, 
p = 0.0017, respectively). Patients in the poor MSKCC risk 
group (n = 75) also had improved PFS (3.3 vs 2.6 months), 
although the difference was not signiﬁ  cant (p = 0.25).
CALGB 90206 revealed no new safety signals for 
the combination of bevacizumab plus IFN regimen (Rini 
et al 2008). The number of grade 3/4 AEs was higher in 
the bevacizumab plus IFN arm compared with the IFN 
arm (79% vs 61%), and the most common events were 
fatigue (37%), anorexia (17%), proteinuria (15%), and 
hypertension (10%).
Comparison with AVOREN
Both AVOREN and CALGB 90206 show that bevacizumab 
plus IFN produces signiﬁ  cant clinical beneﬁ  t as ﬁ  rst-line 
therapy for patients with metastatic RCC. Despite differ-
ences in median PFS between AVOREN and CALGB 90206, 
a comparable beneﬁ  t based on a broad overlap of CIs is 
observed: CALGB 90206, HR = 0.71 (95% CI: 0.61–0.83), 
compared with AVOREN, HR = 0.63 (95% CI: 0.52–0.75). 
However, a cross-trial comparison of the absolute results of 
CALGB 90206 with AVOREN and other trials is inappropri-
ate, as demonstrated by differences in outcomes in the IFN 
monotherapy control arms in ﬁ  rst-line studies (Escudier et al 
2007a; Motzer et al 2007). Although AVOREN and CALGB 
were both phase III trials and used essentially the same treat-
ment regimens, there are a number of potential reasons for 
the observed differences between the 2 studies.
First, CALGB 90206 was an open-label, cooperative 
group study whereas AVOREN was a pivotal, double-blind, 
placebo-controlled, randomized study. The open-label design 
of CALGB 90206, together with the availability of active 
second-line therapies (sunitinib and sorafenib) in the US 
during this trial, may have led to patients discontinuing IFN 
therapy early, prior to disease progression, and potentially 
introducing a bias. This is highlighted by the signiﬁ  cantly 
more frequent use of second-line anti-VEGF therapy in both 
arms of CALGB 90206 compared with AVOREN (bevaci-
zumab plus IFN: 35% vs 15%; IFN: 48% vs 20%).
A number of differences in patient populations between 
CALGB 90206 and AVOREN are also evident. First, prior 
nephrectomy was a requirement for inclusion in the AVO-
REN trial, but not in CALGB 90206. Patients who have 
undergone nephrectomy traditionally beneﬁ  t more from 
IFN therapy: a meta-analysis by Coppin et al concluded 
‘nephrectomy followed by interferon-alfa gives the best 
survival strategy for fully validated therapies’ (Coppin 
et al 2005). Recent data also suggest that patients who have 
undergone nephrectomy have better outcomes than those 
who have not when treated with recently approved agents 
(Szczylik et al 2008). Second, in AVOREN, the propor-
tion of tumor with clear cell histology had to be  50%; 
this was not speciﬁ  ed in CALGB 90206. As histological 
subtype is a signiﬁ  cant prognostic factor in RCC, this could 
have impacted on outcomes (Delahunt et al 2007). Third, a 
greater level of proteinuria was allowed in CALGB 90206 
compared with AVOREN (CALGB 90206:  2 g/24 hours; 
AVOREN:  0.5 g/24 hours), potentially allowing the 
inclusion of patients with a greater degree of renal damage. 
Taking all of these factors into account, the population in 
CALGB 90206 may have had a poorer prognosis than that in 
AVOREN. This is also suggested by the lower than expected 
efﬁ  cacy of IFN monotherapy in the favorable MSKCC risk 
category in CALGB 90206.
Finally, there was a higher incidence of grade 3/4 toxicities 
in CALGB 90206 compared with AVOREN, with the Biologics: Targets & Therapy 2008:2(3) 524
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IFN arm having considerably more toxicity in the CALGB 
90206 study compared with the IFN plus placebo arm in 
AVOREN. IFN is not approved by the FDA for the treatment 
of RCC and is not established as standard of care (IL-2 is the 
only immunotherapeutic agent approved by the FDA for use 
in the treatment of patients with RCC). This suggests that 
limited clinical experience of IFN use in RCC and thus of 
management of IFN-related toxicities may in part be respon-
sible for the higher incidence of grade 3/4 toxicity with IFN 
in CALGB 90206. Despite this, no new safety signals were 
observed in the CALGB 90206 trial.
Summary of clinical experience 
with bevacizumab in RCC
Data from phase II and III trials have shown that therapy with 
bevacizumab is effective and well tolerated in RCC. Recent 
phase III data from the AVOREN trial have demonstrated that 
ﬁ  rst-line bevacizumab plus IFN produces clinically important 
and statistically signiﬁ  cant improvements in PFS and tumor 
response compared with IFN alone, irrespective of patient 
subgroups. Data from CALGB 90206 support the conclusion 
of the AVOREN trial that bevacizumab plus IFN is an effec-
tive ﬁ  rst-line combination, producing clinically meaningful 
beneﬁ  t to patients with metastatic RCC. Bevacizumab plus 
IFN is well tolerated and no new toxicities outside of those 
already known for these 2 therapies have been observed. 
Bevacizumab and IFN have been used clinically for a number 
of years and as such their tolerability proﬁ  les, as well as 
side-effect management, are well established.
When selecting ﬁ  rst-line therapy, 
is best PFS the primary goal?
The approval of a number of new therapies that inhibit 
angiogenesis has revolutionized the treatment options avail-
able for patients with metastatic RCC. During the past few 
years, 4 new drugs have been approved for use in RCC in 
the US and/or Europe: bevacizumab (in combination with 
IFN), sunitinib, sorafenib, and temsirolimus. Because of 
the rapid pace of change in the treatment environment, a 
number of questions and challenges remain when selecting 
the optimal treatment.
When selecting ﬁ  rst-line therapy, is best PFS the primary 
goal? Of the novel agents recently approved for metastatic 
RCC, the greatest PFS beneﬁ  ts are seen with bevacizumab 
plus IFN (10.2 months) and sunitinib (11 months). However, 
a number of patients’ needs, individual risks, and disease-
related factors should be considered when making treatment 
decisions; for example, patient mobility and profession are 
important factors in maintaining a patient’s quality of life 
and can inﬂ  uence the choice of primary therapy.
In considering such factors, the speciﬁ  c tolerability of 
new agents can be used to guide therapy selection to allow 
treatment to be tailored to the individual circumstances of 
the patient. Data for bevacizumab in tumors other than RCC 
indicate that there is a risk of arterial thromboembolic events 
(ATE) when bevacizumab is used with chemotherapy regi-
mens (Hurwitz et al 2004; Sandler et al 2006; Sugrue et al 
2007). Data from phase III trials of bevacizumab in RCC 
have not revealed an increased risk of ATEs to date (Escudier 
et al 2007b; Rini et al 2008), but it is appropriate that care 
should be taken when using bevacizumab in patients with a 
history of ATEs. Alternatively, sunitinib may be the most 
suitable therapeutic option for these patients. Sunitinib has 
been evaluated in patients with brain metastases (Gore et al 
2007) and may be more appropriate for this particular patient 
population as bevacizumab has not been fully investigated in 
these patients. Similarly, sunitinib’s distinct toxicity proﬁ  le 
may prevent it being the ﬁ  rst choice of therapy in patients 
with co-morbidities such as nutritional disorders, where the 
development of diarrhea, nausea and stomatitis/mucositis 
would be especially undesirable. The risk of immobility 
and loss of dexterity through the development of hand-foot 
syndrome with sunitinib therapy may be another factor to 
consider when deciding how to maintain the patient’s daily 
lifestyle, particularly in relation to the wish to continue 
to work. Finally, the potentially greater risk of cardiac 
toxicity in patients treated with sunitinib, which is possibly 
due to inhibition of multiple factors involved in cardio-
myocyte repair and survival in patients with pre-existing 
cardiac damage (Schmidinger et al 2007), may mean that 
other options are needed in patients with a history of heart 
disease. As these particular toxicities are not observed with 
bevacizumab plus IFN, bevacizumab plus IFN would be the 
treatment of choice in these patients (Table 1).
The AVOREN trial demonstrated that reducing the dose 
of IFN can be used to improve further the tolerability of 
therapy while maintaining efﬁ  cacy in patients who are unable 
to tolerate the standard dose of IFN (9 MIU 3 times a week 
subcutaneously) (Melichar et al 2008). Reducing the dose 
of IFN signiﬁ  cantly reduced the incidence of grade  3 AEs 
(Melichar et al 2008), with a considerable reduction in 
incidence in the 6-week period after IFN dose reduction 
compared with the 6 weeks before reduction in patients 
receiving bevacizumab plus lower-dose IFN (18% vs 44%) 
and lower-dose IFN plus placebo (10% vs 41%) (Figure 2). 
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lower-dose IFN was 12.4 months (Figure 3) (Melichar B 
et al 2007). Response rates were also maintained in the IFN 
lower-dose population (bevacizumab plus IFN 34% and IFN 
plus placebo 17% vs bevacizumab plus IFN 32% and IFN plus 
placebo 13% in the total population) (Melichar et al 2008). 
This indicates that IFN dose reduction allows tolerability 
to be managed while the efﬁ  cacy of the bevacizumab plus 
IFN regimen is maintained. Improvements in tolerability by 
reducing the dose of IFN are also observed with sorafenib 
(Bracarda et al 2007b; Gollob et al 2007; Ryan et al 2007).
In summary, a number of parameters, such as patients’ 
needs, individual risks and disease-related factors, as well 
as efﬁ  cacy should all be considered when making treatment 
decisions. The tolerability proﬁ  les of novel therapies can help 
guide ﬁ  rst-line therapy to offer bespoke treatment options to 
suit the needs of the individual patient. The combination of 
bevacizumab plus IFN provides physicians with a ﬂ  exible 
treatment regimen for metastatic RCC and allows the reduc-
tion of IFN dose to improve tolerance and manage toxicity 
without compromising efﬁ  cacy.
Future strategies for providing 
additional beneﬁ  t to patients
Can combination therapy offer greater beneﬁ  t to patients than 
one agent alone? With the approval of a number of novel 
therapies for treatment of RCC, the next logical step is to 
combine them and assess their interaction. Combining direct 
anti-VEGF therapy such as bevacizumab with multi-targeted 
TKIs may increase anti-tumor efficacy by maximizing 
inhibition of the VEGF pathway (Sosman et al 2007). 
Table 1 Summary of the adverse events for sunitinib and 
bevacizumab plus IFN
All grade (%) Sunitinib Bevacizumab plus IFN
Fatigue 51 33
Diarrhea 53 20
Nausea 44 NR
Stomatitis 25 –
Hand-foot syndrome 20 –
Hypertension 24 26
Bleeding 12 33
Thrombocytopenia 65 6
Anemia 71 10
Proteinuria – 18
Abbreviation: IFN, interferon alpha-2a; NR, not reported.
Figure 2 Lowering the dose of IFN improves tolerability.
Abbreviation: IFN, interferon alpha-2a.
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However, tolerability has to be considered when designing 
combinations of different therapies.
Although data to date show that objective responses 
can be achieved by combining bevacizumab with TKIs, an 
increase in the incidence and severity of TKI associated 
toxicity is also observed. A phase I trial assessing the safety 
and maximum tolerated dose of bevacizumab plus sunitinib 
revealed an ORR of 52% (n = 25) (Feldman et al 2008), 
higher than that observed with either bevacizumab plus IFN 
or sunitinib (Escudier et al 2007b; Motzer et al 2007). The 
maximum tolerated dose of bevacizumab and sunitinib deter-
mined by this trial was 10 mg/kg intravenously every 2 weeks 
and sunitinib 50 mg/day for 4 of every 6 weeks. Hypertension 
was the most frequent grade 3/4 event and 2 dose-limiting 
toxicities (DLTs) occurred (grade 4 hemorrhage). To manage 
toxicity, sunitinib dose reduction was required in 40% of 
patients. This study concluded that while bevacizumab plus 
sunitinib was active, this combination was poorly tolerated 
at full doses as a high proportion of patients experienced 
toxicity requiring sunitinib dose reductions and/or study 
discontinuation. This conclusion was echoed in the phase II 
SABRE-R trial of bevacizumab plus sunitinib where the 
same regimen was studied. This trial was stopped due to the 
level of toxicity that was observed with long-term therapy, 
suggesting that this combination cannot be recommended for 
further trial. In contrast to these 2 studies, Cooney et al report 
bevacizumab plus sunitinib is tolerable at full doses without 
unexpected toxicities (Cooney et al 2008). This phase I trial 
investigates various dose combinations of bevacizumab and 
sunitinib in multiple solid tumors. A PR of 30% is reported 
in the total study population evaluable for response (n = 23). 
One patient experienced a DLT (grade 4 hypertension) with 
37.5 mg sunitinib and 5 mg/kg bevacizumab, with grade 3 
hypertension occurring in 13 other patients.
Combining bevacizumab plus sorafenib showed a PR 
rate of 46% (n = 46), with a TTP of 11.2 months (Sosman 
et al 2008). However, sorafenib-associated DLTs (hand-foot 
syndrome and anorexia) prevented full-dose combination 
therapy. As combination of lower doses of these agents 
appears both feasible and to have high activity, further studies 
are being performed (see below).
Temsirolimus inhibits mammalian target of rapamycin 
(mTOR) signaling as opposed to bevacizumab, sunitinib and 
sorafenib which inhibit the VEGF pathway. This different 
mechanism of action suggests that it should be combinable 
with bevacizumab and other agents. However, a phase I trial 
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indicated that sunitinib plus temsirolimus has unacceptable 
toxicity (Fischer et al 2008). In contrast, a dose-escalation 
trial of bevacizumab (5–10 mg/kg every 2 weeks) plus tem-
sirolimus (10–25 mg weekly) showed that 8 of 12 patients 
had PRs, for an ORR of 67% (Merchan et al 2007). A further 
3 patients had stable disease as their best response, for a 
clinical beneﬁ  t rate of 92%. Two DLTs occurred (grade 3 
hypertriglyceridemia, grade 3 stomatitis), but no grade 4 
toxicities related to therapy occurred. The combinability 
of bevacizumab with mTOR inhibitors was further demon-
strated by the phase II trial of bevacizumab in combination 
with everolimus (RAD001) (Whorf et al 2008). Patients 
received bevacizumab 10 mg/kg every 2 weeks and 
everolimus 10 mg daily. An objective response of 21% and 
a minor response/stable disease of 69% was observed in 
the 90% of patients who completed 8 weeks of treatment. 
Grade 3/4 proteinuria occurred in 10 patients (19%) but 
other grade 3/4 toxicity was uncommon (fatigue 9%, stoma-
titis 8%). These data suggest that the combination of beva-
cizumab with everolimus is active and tolerable treatment 
for metastatic clear cell RCC.
The data described above suggest bevacizumab can be 
combined with a range of novel agents (Figure 4). However, 
trials in which sunitinib or sorafenib have been combined 
with other agents show that combinations including these 
agents are poorly tolerated or that signiﬁ  cant dose reduction 
is required to ensure tolerability, with considerable loss of 
efﬁ  cacy (Sosman et al 2006; Jonasch et al 2007; Kondagunta 
et al 2007; Ryan et al 2007).
Larger, more robust studies are required to investi-
gate whether combinations of novel agents will offer true 
beneﬁ  t to patients with metastatic RCC. Bevacizumab in 
combination with sorafenib or temsirolimus is currently 
being studied in 3 trials of combination therapy in RCC. 
The BeST trial is a 4-arm, randomized phase II trial that will 
compare the efﬁ  cacy and safety of bevacizumab, sorafenib 
and temsirolimus combinations to those of bevacizumab 
alone. A second trial, trial 3311, is a 2-arm phase III trial 
comparing bevacizumab plus IFN with bevacizumab plus 
temsirolimus in 822 patients. TORAVA, a French phase II 
trial, is ongoing and will compare sunitinib with bevacizumab 
plus IFN and bevacizumab plus temsirolimus.
Because novel therapies target different pathways, it 
is possible that sequential use of agents may have further 
efﬁ  cacy following disease progression. This strategy is 
being investigated by several phase I/II trials to identify 
the optimal sequence of therapy that can improve patient 
outcomes.
Combination partner
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Figure 4 Bevacizumab is a good partner for combination therapy.
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In patients who become refractory to bevacizumab 
therapy, sunitinib and sorafenib appear to be effective as 
second-line agents (Drabkin et al 2007; Hutson et al 2007). 
Sunitinib following ﬁ  rst-line bevacizumab achieved an 
ORR in 61 patients of 23% (14 PRs, 36 stable diseases), 
with a PFS of 30 weeks (Hutson et al 2007). The most 
common treatment-related AEs were fatigue, diarrhea, 
and nausea. A subgroup analysis of patients enrolled on 
the sorafenib expanded access trial who had received 
prior bevacizumab therapy showed that stable disease was 
achieved in 77% of patients (n = 197) treated with sorafenib 
(Drabkin et al 2007). The most frequent grade 3/4 toxicities 
were hand-foot syndrome, fatigue and hypertension. The 
incidence of AEs leading to dose interruption, reduc-
tion, or discontinuation of sorafenib was 39%, 20%, and 
26% respectively.
Summary of bevacizumab in RCC
Data from 2 large phase III trials show that bevacizumab is an 
effective ﬁ  rst-line therapy for the treatment of metastatic RCC, 
offering signiﬁ  cant extension in PFS and improved response 
rate when used in combination with IFN. Bevacizumab plus 
IFN is well tolerated, with dose reduction of IFN providing 
the ﬂ  exibility to improve tolerability further. The overall 
tolerability proﬁ  le of bevacizumab plus IFN in comparison 
with other agents available for ﬁ  rst-line treatment of RCC is 
important when tailoring therapy for individual patients.
With a number of novel therapies approved for the treat-
ment of RCC, it will be vital to optimize combination and/or 
sequencing strategies to ensure that the use of all available 
therapies is optimized to maximize beneﬁ  t for patients with 
metastatic RCC. Data to date and tolerability proﬁ  les favor 
bevacizumab as a combination partner and, consequently, 
randomized trials have been initiated to address bevaci-
zumab’s potential. Before starting ﬁ  rst-line therapy, the 
complete sequence of treatment should also be considered. 
Current data suggest that bevacizumab has maximal beneﬁ  t 
when used ﬁ  rst line (Bukowski et al 2007; Escudier et al 
2007b) and, therefore, approaches based on this observation, 
with bevacizumab administered on diagnosis of metastatic 
RCC and other agents administered on progression, may be 
reasonable. Bevacizumab has a central role to play in future 
advances in RCC therapy.
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